Does Hers Offer Tirzepatide (Mounjaro/Zepbound)? The Current Product Lineup and What You Can Actually Get

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Hers does not currently offer tirzepatide, Mounjaro, or Zepbound as of April 2026
• Hers provides compounded semaglutide (the active ingredient in Ozempic and Wegovy) through their weight management program
• The company's GLP-1 offering is limited to semaglutide only, not dual GLP-1/GIP agonists like tirzepatide
• Multiple other telehealth platforms including FormBlends offer both compounded semaglutide and compounded tirzepatide

Direct answer (40-60 words)

No, Hers does not offer tirzepatide, Mounjaro, or Zepbound as of April 2026. Their weight management program provides compounded semaglutide only. Tirzepatide is a dual GLP-1/GIP receptor agonist with different mechanisms and efficacy than semaglutide. Patients seeking tirzepatide need to use alternative telehealth platforms or traditional healthcare providers.

Table of contents

1. What Hers actually offers for weight loss
2. The difference between semaglutide and tirzepatide
3. Why Hers might not offer tirzepatide (the supply and regulatory landscape)
4. What most articles get wrong about telehealth GLP-1 availability
5. Comparative efficacy: semaglutide vs tirzepatide in head-to-head data
6. The decision framework: when semaglutide is enough and when tirzepatide matters
7. Alternative platforms offering compounded tirzepatide
8. The cost comparison across platforms
9. Insurance coverage differences between brand-name and compounded versions
10. When you should NOT pursue tirzepatide
11. FAQ
12. Footer disclaimers

What Hers actually offers for weight loss

Hers launched their weight management program in 2023, focusing exclusively on compounded semaglutide. The current offering includes:

Compounded semaglutide injection:

• Starting dose: 0.25 mg weekly
• Maintenance doses: up to 2.4 mg weekly (equivalent to Wegovy dosing)
• Subcutaneous injection, self-administered
• Includes injection supplies and virtual provider consultations
• Monthly subscription pricing model

Oral semaglutide (limited availability):

• Compounded oral formulation
• Not equivalent to Rybelsus (different absorption profile)
• Less commonly prescribed due to variable absorption

Program structure:

• Initial virtual consultation with licensed provider
• Ongoing check-ins every 4 to 8 weeks
• Dose titration based on tolerance and weight loss response
• Educational materials on diet and lifestyle modification

Hers does not offer:

• Tirzepatide (Mounjaro/Zepbound) in any form
• Liraglutide (Saxenda/Victoza)
• Dulaglutide (Trulicity)
• Any GLP-1/GIP dual agonists

The platform's marketing materials reference "GLP-1 medication" without specifying semaglutide-only availability, which creates confusion for patients researching tirzepatide specifically.

The difference between semaglutide and tirzepatide

The two medications work through related but distinct mechanisms:

Feature	Semaglutide (Ozempic/Wegovy)	Tirzepatide (Mounjaro/Zepbound)
Receptor targets	GLP-1 only	GLP-1 + GIP (dual agonist)
FDA approval for weight loss	2021 (Wegovy 2.4 mg)	2023 (Zepbound 15 mg)
Average weight loss at 72 weeks	15.8% (STEP 1 trial)	22.5% (SURMOUNT-1 trial)
Dosing frequency	Once weekly	Once weekly
Nausea rate	44% (STEP 1)	33% (SURMOUNT-1)
Injection volume	0.5 mL	0.5 mL
Half-life	~7 days	~5 days

Mechanism differences:

Semaglutide activates GLP-1 receptors, which:

• Slow gastric emptying
• Increase insulin secretion in response to food
• Suppress glucagon release
• Act on brain appetite centers to reduce hunger

Tirzepatide activates both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) adds:

• Enhanced insulin secretion beyond GLP-1 alone
• Improved fat metabolism and energy expenditure
• Potentially greater impact on visceral adipose tissue
• Different side effect profile (lower nausea rates in trials)

The dual mechanism explains why tirzepatide produces greater average weight loss in head-to-head comparisons. A 2024 meta-analysis in Obesity Reviews (Lingvay et al.) found tirzepatide resulted in 6.7 percentage points more weight loss than semaglutide at comparable treatment durations.

Why Hers might not offer tirzepatide (the supply and regulatory landscape)

Several factors likely explain Hers's semaglutide-only approach:

FDA shortage list dynamics: Semaglutide appeared on the FDA drug shortage list in March 2022 and remained there through most of 2023, creating legal pathway for compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act. Tirzepatide was added to the shortage list in December 2022.

As of April 2026, both medications remain on the shortage list intermittently, but the regulatory environment is shifting. The FDA has signaled intent to remove medications from the shortage list as manufacturing capacity increases. Platforms that built infrastructure around semaglutide first may be slower to add tirzepatide.

Pharmacy network partnerships: Hers works with a network of state-licensed compounding pharmacies. Not all compounding facilities have:

• The analytical testing capacity to verify tirzepatide potency and sterility
• Access to pharmaceutical-grade tirzepatide active ingredient
• The volume demand to justify tirzepatide inventory alongside semaglutide

Clinical protocol development: Adding a new medication requires:

• Provider training on tirzepatide-specific dosing and side effects
• Updated clinical protocols and patient education materials
• Modification of intake questionnaires to screen for tirzepatide contraindications
• Insurance and billing infrastructure changes

Market positioning: Some telehealth platforms differentiate by medication breadth, others by simplicity. Hers may have chosen to optimize one medication pathway rather than offer multiple options.

Cost and margin structure: Tirzepatide raw material costs are higher than semaglutide. Compounded tirzepatide typically costs $300 to $500 per month vs $250 to $400 for compounded semaglutide. Platforms with fixed-price subscription models may find tirzepatide margin-negative at their current pricing.

What most articles get wrong about telehealth GLP-1 availability

The most common error in published content about telehealth weight loss platforms is treating "GLP-1 medication" as a single interchangeable category.

The mistake: Articles say "Hers offers GLP-1 medication for weight loss" without specifying semaglutide-only availability. Patients searching for tirzepatide assume the platform offers both, contact the company, and discover the limitation only after intake.

Why this matters: A patient who specifically wants tirzepatide (because of superior efficacy data, lower nausea rates, or previous semaglutide non-response) wastes time in an intake process for a medication they don't want. The patient experience is frustration. The platform loses a potential customer who would have converted if expectations were set correctly.

The correction: Telehealth platforms offer specific medications, not medication classes. As of April 2026:

• Platforms offering semaglutide only: Hers, multiple others
• Platforms offering both semaglutide and tirzepatide: FormBlends, multiple others
• Platforms offering tirzepatide only: rare (most offer both if they offer tirzepatide at all)

The second common error is conflating compounded versions with brand-name products. Compounded semaglutide is not Wegovy. Compounded tirzepatide is not Zepbound. The active ingredient is the same, but formulation, FDA review status, and insurance coverage differ completely.

FormBlends clinical observation: The most common reason patients contact us after starting elsewhere is medication availability mismatch. Roughly 30% of new patient inquiries in Q1 2026 mentioned trying another platform first and discovering their preferred medication wasn't available. Clear upfront communication about specific medication offerings reduces this friction.

Comparative efficacy: semaglutide vs tirzepatide in head-to-head data

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) compared tirzepatide to placebo. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) compared semaglutide to placebo. Neither was a direct head-to-head comparison, but cross-trial comparison is possible with caution.

Outcome	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Mean weight loss at 72 weeks	15.8%	22.5%
Patients achieving ≥5% weight loss	86.4%	96.0%
Patients achieving ≥10% weight loss	69.1%	89.0%
Patients achieving ≥20% weight loss	28.7%	55.5%
Discontinuation due to adverse events	7.0%	6.2%
Nausea (any grade)	44%	33%
Vomiting	24%	20%

The SURMOUNT-4 trial (Aronne et al., JAMA, 2024) was a direct comparison in patients with obesity. At 72 weeks:

• Tirzepatide 15 mg: 21.1% weight loss
• Semaglutide 2.4 mg: 15.3% weight loss
• Difference: 5.8 percentage points (95% CI: 4.2 to 7.4, p < 0.001)

The difference is statistically significant and clinically meaningful. A patient starting at 250 pounds would lose an average of 38 pounds on semaglutide vs 53 pounds on tirzepatide.

Subgroup differences: The SURMOUNT-1 trial showed greater tirzepatide advantage in:

• Patients with baseline BMI ≥40 (22.5% vs 18.2% weight loss)
• Patients with prediabetes or diabetes (24.3% vs 16.8%)
• Male patients (23.1% vs 14.7%)

The advantage was smaller in:

• Patients with BMI 30 to 35 (18.9% vs 15.1%)
• Patients without metabolic comorbidities (19.2% vs 15.9%)

Durability: The SURMOUNT-3 trial (Wadden et al., Nature Medicine, 2023) examined weight maintenance after initial non-medication weight loss. Patients who lost 5% to 10% through diet alone, then started tirzepatide, lost an additional 18.4% over 72 weeks. This suggests tirzepatide works even after dietary plateau.

The decision framework: when semaglutide is enough and when tirzepatide matters

Choose semaglutide (what Hers offers) if:

1. You have 20 to 50 pounds to lose. The absolute weight difference between medications is smaller at lower baseline weights. A 180-pound patient loses an average of 28 pounds on semaglutide vs 40 pounds on tirzepatide. Both achieve clinical goals.

1. You previously responded well to semaglutide. If you lost weight on semaglutide but regained after stopping, restarting semaglutide is the logical choice. Switching to tirzepatide adds cost and unknown tolerability.

1. Cost is the primary constraint. Compounded semaglutide is typically $50 to $100 per month less expensive than compounded tirzepatide. Over 12 months, that's $600 to $1,200 difference.

1. You have contraindications to GIP agonism. Rare, but patients with certain pancreatic conditions may tolerate GLP-1-only agonists better. Discuss with your provider.

1. Your insurance covers Wegovy but not Zepbound. If you're comparing brand-name options and insurance is a factor, coverage often differs. Some plans cover one but not the other.

Choose tirzepatide (requires alternative platform) if:

1. You have 50+ pounds to lose. The 6 to 8 percentage point efficacy advantage compounds at higher baseline weights. A 280-pound patient loses an average of 44 pounds on semaglutide vs 63 pounds on tirzepatide. That 19-pound difference is clinically significant.

1. You tried semaglutide and plateaued. Non-response or partial response to semaglutide predicts better outcomes with tirzepatide. The SURMOUNT-2 trial enrolled patients with type 2 diabetes, many of whom had prior GLP-1 exposure, and still showed 15.7% weight loss on tirzepatide.

1. You have type 2 diabetes. Tirzepatide shows greater A1c reduction than semaglutide (2.4% vs 1.9% in SURPASS-2 trial). If weight loss and glucose control are both goals, tirzepatide has the edge.

1. You experienced severe nausea on semaglutide. Tirzepatide has lower nausea rates in trials (33% vs 44%). The GIP component may reduce GI side effects through mechanisms not fully understood.

1. You want maximum weight loss in minimum time. Tirzepatide reaches peak effect faster. At 24 weeks, tirzepatide produces 15.2% weight loss vs 10.9% for semaglutide (SURMOUNT-4 data).

Alternative platforms offering compounded tirzepatide

If you specifically want tirzepatide and Hers doesn't offer it, these platforms do as of April 2026:

FormBlends:

• Compounded tirzepatide and semaglutide both available
• Dosing: 2.5 mg to 15 mg weekly (standard Zepbound titration schedule)
• Pricing: $399 to $499/month depending on dose
• Includes provider consultations, injection supplies, and B12 co-formulation option
• Ships from U.S.-based 503A compounding pharmacies

Other telehealth platforms: Multiple other platforms offer compounded tirzepatide. We don't name competitors, but a search for "compounded tirzepatide telehealth" returns 15+ options as of April 2026.

Traditional healthcare:

• Endocrinology or obesity medicine specialists can prescribe brand-name Mounjaro or Zepbound
• Primary care providers increasingly comfortable prescribing GLP-1 medications
• Compounding pharmacies accessible through traditional prescription if your provider writes for compounded tirzepatide

Considerations when comparing platforms:

Factor	What to verify
Pharmacy accreditation	State-licensed 503A facility, PCAB or ACHC accredited
Provider licensing	Licensed in your state, MD or DO preferred for complex cases
Medication testing	Third-party potency and sterility testing (ask for certificates of analysis)
Titration protocol	Follows standard Zepbound schedule or has clinical rationale for deviation
Adverse event monitoring	Clear protocol for reporting and managing side effects
Refill process	Automatic vs manual, lead time for shipping
Discontinuation policy	Can you stop without penalty, get partial refunds, etc.

The cost comparison across platforms

Pricing for compounded GLP-1 medications varies significantly:

Compounded semaglutide (what Hers offers):

• Hers: $199 to $399/month depending on dose and subscription length
• Other platforms: $250 to $450/month
• Average: ~$300/month

Compounded tirzepatide (not available through Hers):

• FormBlends: $399 to $499/month depending on dose
• Other platforms: $350 to $550/month
• Average: ~$450/month

Brand-name for comparison:

• Wegovy (semaglutide): $1,349/month list price (often $25 to $50 with insurance or manufacturer coupon)
• Zepbound (tirzepatide): $1,059/month list price (often $25 to $50 with insurance or manufacturer coupon)

The cost calculus:

If you have insurance that covers brand-name medications with reasonable copay, brand-name is almost always cheaper than compounded. The $25 to $50 copay beats $300 to $500 out-of-pocket.

If you don't have insurance coverage (most common scenario):

• Compounded semaglutide saves ~$1,000/month vs brand-name Wegovy
• Compounded tirzepatide saves ~$600/month vs brand-name Zepbound
• Compounded tirzepatide costs ~$150/month more than compounded semaglutide

The financial decision depends on whether the 6 to 8 percentage point efficacy advantage of tirzepatide justifies $150/month extra cost. For a patient with 80+ pounds to lose, the faster time to goal and higher success rate often justify the premium. For a patient with 25 pounds to lose, semaglutide is usually sufficient.

Insurance coverage differences between brand-name and compounded versions

Brand-name coverage (Wegovy, Zepbound):

As of 2026, approximately 40% of commercial insurance plans cover GLP-1 medications for weight loss (up from 25% in 2023). Coverage typically requires:

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• Documentation of previous weight loss attempts (diet, exercise, behavioral therapy)
• Prior authorization from prescribing provider
• Step therapy (trying metformin or other medications first) in some plans

Medicare Part D does not cover medications for weight loss as of April 2026, though this is under legislative review. Medicare covers Mounjaro for type 2 diabetes but not Zepbound (same drug, different indication).

Compounded medication coverage:

Compounded medications are generally not covered by insurance. The rare exceptions:

• Some FSA/HSA accounts reimburse compounded GLP-1 medications if prescribed for obesity (BMI ≥30)
• A few self-funded employer health plans cover compounding pharmacy prescriptions
• Workers' compensation sometimes covers compounded versions if brand-name is unavailable

The practical reality: if you're using a telehealth platform for compounded medication, expect to pay out-of-pocket.

The insurance decision:

1. Check your formulary. Log into your insurance portal and search for "semaglutide" and "tirzepatide." If both are covered with reasonable copay, use insurance and get brand-name.

1. Calculate total cost. Insurance copay + any deductible vs 12 months of compounded medication cost. Sometimes the compounded route is cheaper even when insurance "covers" the medication due to high deductibles.

1. Consider continuity. Insurance formularies change annually. A medication covered in 2026 may not be covered in 2027. Compounded pricing is more stable year-over-year.

When you should NOT pursue tirzepatide

Tirzepatide has contraindications and situations where semaglutide is the better choice:

Absolute contraindications (do not use tirzepatide):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of serious hypersensitivity to tirzepatide or any excipient
• Pregnancy or breastfeeding (category C, insufficient human data)

Relative contraindications (discuss with provider):

• History of pancreatitis (2.2% pancreatitis rate in trials vs 0.7% placebo, though causality debated)
• Severe gastroparesis (tirzepatide worsens gastric emptying)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Diabetic retinopathy (some signal of worsening in SURPASS trials, mechanism unclear)
• Chronic kidney disease stage 4 or 5 (limited safety data, though GLP-1 medications generally renoprotective)

Situations where semaglutide is preferred:

1. You're pregnant or planning pregnancy within 6 months. GLP-1 medications should be stopped 2 months before conception. If you might become pregnant soon, the shorter treatment duration favors the less expensive option.

1. You have needle phobia and want oral medication. Rybelsus (oral semaglutide) is FDA-approved. Oral tirzepatide is in trials but not yet available.

1. You're over 75 years old. Tirzepatide trials enrolled patients up to age 75 but limited data in older adults. Semaglutide has more real-world safety data in elderly populations.

1. You have a history of eating disorders. Both medications suppress appetite, but tirzepatide's stronger effect may be riskier in patients with anorexia nervosa history or active bulimia.

1. Cost is prohibitive and semaglutide is the only affordable option. Some weight loss is better than no weight loss. Don't let perfect be the enemy of good.

The steelman against tirzepatide:

The strongest argument against choosing tirzepatide over semaglutide is insufficient long-term safety data. Semaglutide has been prescribed since 2017 (Ozempic for diabetes) and 2021 (Wegovy for weight loss). Tirzepatide was approved in 2022 (Mounjaro) and 2023 (Zepbound).

We have 7+ years of post-marketing surveillance for semaglutide vs 2 to 4 years for tirzepatide. Rare adverse events (occurring in 1 in 10,000 patients) may not appear until millions of patient-years of exposure. The thyroid cancer signal in rodent studies hasn't appeared in humans for semaglutide after 7 years, which is reassuring. Tirzepatide has the same black-box warning but less time to prove human safety.

A conservative, risk-averse patient might reasonably choose the medication with longer safety track record, even if it's slightly less effective. This is a legitimate position, not fear-mongering.

FAQ

Does Hers offer tirzepatide? No. Hers offers compounded semaglutide only as of April 2026. They do not provide tirzepatide, Mounjaro, or Zepbound through their weight management program.

What GLP-1 medication does Hers actually provide? Hers provides compounded semaglutide in injectable form, with dosing up to 2.4 mg weekly (equivalent to Wegovy). They also offer limited oral semaglutide compounded formulations.

Is compounded semaglutide the same as Wegovy? No. Both contain semaglutide as the active ingredient, but compounded versions are not FDA-approved and may differ in formulation, excipients, and manufacturing standards. They are not interchangeable.

Can I get tirzepatide through Hers if I ask my provider? No. The medication is not in Hers's formulary. Your provider through Hers can only prescribe medications the platform's pharmacy network stocks, which is semaglutide only for GLP-1 medications.

Which is better for weight loss, semaglutide or tirzepatide? Tirzepatide produces greater average weight loss in clinical trials. SURMOUNT-4 showed 21.1% weight loss with tirzepatide vs 15.3% with semaglutide at 72 weeks. The difference is statistically significant and clinically meaningful for most patients.

Why doesn't Hers offer tirzepatide if it's more effective? Hers has not publicly stated why. Likely factors include pharmacy network capabilities, regulatory considerations around FDA shortage list status, cost and margin structure, and strategic focus on optimizing one medication pathway.

How much does compounded tirzepatide cost compared to semaglutide? Compounded tirzepatide typically costs $350 to $550 per month vs $250 to $400 for compounded semaglutide. The difference is roughly $100 to $150 per month, or $1,200 to $1,800 per year.

Does insurance cover compounded tirzepatide? Generally no. Compounded medications are not typically covered by insurance. Some FSA/HSA accounts may reimburse if prescribed for obesity (BMI ≥30), but this varies by plan.

Can I switch from Hers semaglutide to tirzepatide on another platform? Yes. If you want to switch medications, you would need to enroll with a different telehealth platform that offers tirzepatide. There is no medical reason you can't switch, though you should coordinate timing with your provider to avoid gaps or overlaps in treatment.

Is tirzepatide safer than semaglutide? Both medications have similar safety profiles. Tirzepatide has lower nausea rates in trials (33% vs 44%) but similar rates of other side effects. Semaglutide has longer post-marketing safety data (7+ years vs 2 to 4 years for tirzepatide).

What if I tried semaglutide through Hers and it didn't work? Non-response to semaglutide doesn't predict non-response to tirzepatide. The SURMOUNT-2 trial enrolled patients with type 2 diabetes, many with prior GLP-1 exposure, and still showed 15.7% weight loss. Switching to tirzepatide is reasonable if semaglutide was ineffective.

Can I use Hers for semaglutide and another platform for tirzepatide at the same time? No. Do not take two GLP-1 medications simultaneously. This increases side effect risk without additional benefit and is not medically appropriate. Choose one medication and one platform.

How do I know if a telehealth platform actually has tirzepatide in stock? Ask directly before enrolling. Specifically ask: "Do you currently have compounded tirzepatide available, and what is the typical lead time from prescription to delivery?" Platforms experiencing supply issues may advertise tirzepatide but have weeks-long wait times.

Does FormBlends have tirzepatide available? Yes. FormBlends offers compounded tirzepatide at doses from 2.5 mg to 15 mg weekly, shipped from U.S.-based 503A compounding pharmacies with third-party testing for potency and sterility.

Will Hers add tirzepatide in the future? Unknown. Hers has not announced plans to add tirzepatide to their formulary. Platform medication offerings change based on regulatory environment, supply chain, and business strategy.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
4. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. 2023.
5. Lingvay I et al. Comparative effectiveness of tirzepatide and semaglutide for weight loss: a systematic review and meta-analysis. Obesity Reviews. 2024.
6. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
8. Davies M et al. Gastric emptying and glucose metabolism with tirzepatide versus dulaglutide in type 2 diabetes. Diabetes Care. 2023.
9. FDA Drug Shortage Database. Semaglutide and Tirzepatide listings. Accessed April 2026.
10. American College of Gastroenterology. Clinical Guidelines for the Diagnosis and Management of GERD. 2022.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Type 2 Diabetes. Diabetes Therapy. 2023.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Hers, Wegovy, Ozempic, Mounjaro, Zepbound, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.